Design Therapeutics price target raised to $20 from $12 at Piper Sandler

Piper Sandler raised the firm’s price target on Design Therapeutics (DSGN) to $20 from $12 and keeps an Overweight rating on the shares. The firm caught up with management following Q1 earnings where it learned new details on DT-216P2’s Phase 1/2 RESTORE-FA which has data in the second half of 2026. Design unveiled dose selection in RESTORE-FA, color on frataxin measurement in whole blood and muscle where any significant frataxin change is considered clinically meaningful. Additionally, RESTORE-FA is assessing exploratory clinical endpoints where Piper learned tidbits related to clinically meaningful thresholds. Hence, the firm believes this update is informative and positions RESTORE-FA not only to answer key questions supporting clinic PoC but also inform probability of future approval.